Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results

Cotinga Pharmaceuticals (TSXV:COT) has announced its financial and operating results for Q4 and full year ended April 30, 2018.

As quoted in the press release:

Advanced the clinical development of COTI-2:

• In March 2018, Cotinga submitted an updated clinical package to regulatory authorities to expand its ongoing clinical trial of COTI-2. The protocol amendment expanded the clinical trial to evaluate COTI-2 as a combination therapy in a wide spectrum of cancers.
• In April 2018, Cotinga and its collaborators from MD Anderson Cancer Center and Northwestern Medicine presented data on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois.
• Subsequent to the reporting quarter, in May 2018, Cotinga announced the clearance of a protocol amendment for its ongoing clinical trial of COTI-2. The multi-part protocol amendment expanded the Phase 1b/2a trial to evaluate COTI-2 as a combination therapy in a wide spectrum of cancers.
• Subsequent to the reporting quarter, in June 2018, Cotinga and its collaborators from MD Anderson Cancer Center presented data on COTI-2 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Secured funding to support clinical development:

• Subsequent to the reporting quarter, in May 2018, Cotinga closed a brokered and non-brokered private placement for total proceeds of approximately $2.010 million to support the continued clinical development of COTI-2. Roth Capital Partners, LLC acted as sole placement agent for the brokered offering in the United States.

Click here to read the full press release.